CPI 1429
Latest Information Update: 03 Jun 2004
At a glance
- Originator Renovis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 29 Feb 2004 Discontinued - Preclinical for Inflammatory bowel disease in USA (PO)
- 12 Dec 2002 Centaur Pharmaceuticals has been acquired by Renovis
- 03 Jan 2001 Centaur Pharmaceuticals is seeking a development partner for CPI 1429 (http://www.centpharm.com)